• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Large owner Tpg Gp A, Llc bought $950,400 worth of shares (60,000 units at $15.84) (SEC Form 4)

    7/1/25 5:03:20 PM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SION alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    TPG GP A, LLC

    (Last) (First) (Middle)
    C/O TPG INC.
    301 COMMERCE STREET, SUITE 3300

    (Street)
    FORT WORTH TX 76102

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Sionna Therapeutics, Inc. [ SION ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/27/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/27/2025 P 60,000 A $15.84 6,744,962 I See Explanation of Responses(1)(2)(3)(4)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    TPG GP A, LLC

    (Last) (First) (Middle)
    C/O TPG INC.
    301 COMMERCE STREET, SUITE 3300

    (Street)
    FORT WORTH TX 76102

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    COULTER JAMES G

    (Last) (First) (Middle)
    C/O TPG GLOBAL, LLC
    301 COMMERCE STREET, SUITE 3300

    (Street)
    FORT WORTH TX 76102

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    WINKELRIED JON

    (Last) (First) (Middle)
    C/O TPG GLOBAL, LLC
    301 COMMERCE STREET, SUITE 3300

    (Street)
    FORT WORTH TX 76102

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    Explanation of Responses:
    1. Each of James G. Coulter and Jon Winkelried own entities that control TPG GP A, LLC (together with Messrs. Coulter and Winkelried, the "Reporting Persons"), which is the managing member of each of (i) TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., and (ii) Alabama Investments (Parallel) GP, LLC, which is the general partner of each of (a) Alabama Investments (Parallel), LP, (b) Alabama Investments (Parallel) Founder A, LP and (c) Alabama Investments (Parallel) Founder G, LP, which, collectively with TPG Group Holdings (SBS), L.P., Alabama Investments (Parallel), LP and Alabama Investments (Parallel) Founder A, LP, holds 100% of the shares of Class B common stock (which represents a majority of the combined voting power of the common stock) of TPG Inc.
    2. TPG Inc. is the sole member of TPG GPCo, LLC, which is the sole member of TPG Holdings II-A, LLC, which is the general partner of TPG Operating Group II, L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Operating Group I, L.P., which is the sole member of The Rise Fund GenPar Advisors, LLC, which is the general partner of The Rise Fund GenPar, L.P., which is the managing member of The Rise Fund SPV GP, LLC, which is the general partner of each of The Rise Fund Sling, L.P., which directly holds 5,536,598 shares of Common Stock ("Common Stock") of Sionna Therapeutics, Inc. (the "Issuer"), and The Rise Fund Sling II, L.P. (together with The Rise Fund Sling, L.P., the "TPG Funds"), which directly holds 1,208,364 shares of Common Stock.
    3. Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each of the TPG Funds and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such TPG Fund's or such Reporting Person's pecuniary interest therein, if any.
    4. Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.
    Remarks:
    5. The Reporting Persons are jointly filing this Form 4 pursuant to Rule 16a-3(j) under the Exchange Act. 6. Gerald Neugebauer is signing on behalf of Messrs. Coulter and Winkelried pursuant to authorization and designation letters dated January 10, 2024, which were previously filed with the Securities and Exchange Commission.
    /s/ Martin Davidson, Chief Accounting Officer, TPG GP A, LLC (5) 07/01/2025
    /s/ Gerald Neugebauer, on behalf of James G. Coulter (5) (6) 07/01/2025
    /s/ Gerald Neugebauer, on behalf of Jon Winkelried (5) (6) 07/01/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SION alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SION

    DatePrice TargetRatingAnalyst
    9/3/2025$45.00Strong Buy
    Raymond James
    9/3/2025$22.00Sector Perform
    RBC Capital Mkts
    3/4/2025Buy
    TD Cowen
    3/4/2025$32.00Buy
    Stifel
    3/4/2025$45.00Buy
    Guggenheim
    More analyst ratings

    $SION
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference

    Phase 1 data of first-in-class NBD1 stabilizers, SION-719 and SION-451, demonstrated they were generally well tolerated and exceeded desired pharmacokinetic targets New preclinical data show that NBD1 stabilizers restored the half-life of F508del-CFTR up to wild-type levels WALTHAM, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced data presented at the 2025 North American Cystic Fi

    10/24/25 1:15:00 PM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis

    SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosis Topline data expected in mid-2026 WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced initiation of the PreciSION CF Phase 2a proof-of-concept (POC) trial evaluating SION-719, a first-in-class nucleotide binding domain 1 (NBD1) stabilizer, when added to Trikafta® (elexacaftor/tezacaftor

    10/21/25 7:00:00 AM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference

    WALTHAM, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that data will be presented at the 2025 North American Cystic Fibrosis Conference (NACFC) being held in Seattle, Washington on October 22-25, 2025. Details of the presentation and posters are as follows: Title: Safety, tolerability, and pharmacokinetics of novel NBD1 stabilizers SION-719 and SION-451 from two phase 1 first-in

    10/1/25 4:05:00 PM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SION
    SEC Filings

    View All

    SEC Form 144 filed by Sionna Therapeutics Inc.

    144 - Sionna Therapeutics, Inc. (0002036042) (Subject)

    10/24/25 6:05:22 PM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Sionna Therapeutics Inc.

    144 - Sionna Therapeutics, Inc. (0002036042) (Subject)

    10/24/25 6:00:01 PM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Sionna Therapeutics Inc.

    144 - Sionna Therapeutics, Inc. (0002036042) (Subject)

    10/24/25 5:53:47 PM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SION
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Cloonan Michael exercised 99,800 shares at a strike of $6.11 and sold $3,618,560 worth of shares (99,800 units at $36.26) (SEC Form 4)

    4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)

    10/22/25 5:39:46 PM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Booth Bruce sold $3,041,683 worth of shares (88,878 units at $34.22) (SEC Form 4)

    4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)

    10/21/25 5:12:03 PM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Booth Bruce sold $9,251,102 worth of shares (286,369 units at $32.30) (SEC Form 4)

    4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)

    10/20/25 9:39:54 PM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SION
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James initiated coverage on Sionna Therapeutics with a new price target

    Raymond James initiated coverage of Sionna Therapeutics with a rating of Strong Buy and set a new price target of $45.00

    9/3/25 8:39:08 AM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on Sionna Therapeutics with a new price target

    RBC Capital Mkts initiated coverage of Sionna Therapeutics with a rating of Sector Perform and set a new price target of $22.00

    9/3/25 8:38:58 AM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on Sionna Therapeutics

    TD Cowen initiated coverage of Sionna Therapeutics with a rating of Buy

    3/4/25 8:27:05 AM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SION
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tpg Gp A, Llc bought $950,400 worth of shares (60,000 units at $15.84) (SEC Form 4)

    4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)

    7/1/25 5:03:20 PM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Tpg Gp A, Llc converted options into 4,875,547 shares and bought $20,250,000 worth of shares (1,125,000 units at $18.00) (SEC Form 4)

    4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)

    2/12/25 5:21:33 PM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SION
    Leadership Updates

    Live Leadership Updates

    View All

    Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer

    WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced the appointment of Caroline Stark Beer, MBA, as its Chief Business Officer (CBO). "We are delighted to welcome Caroline to our executive team at such a pivotal stage for Sionna," said Mike Cloonan, President and Chief Executive Officer of Sionna. "Caroline's exceptional experience, leadership, and value creation mindset will

    9/8/25 8:00:00 AM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SION
    Financials

    Live finance-specific insights

    View All

    Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis

    SION-719 and SION-451 were generally well tolerated and achieved desired pharmacokinetic targets that reinforce their potential as either an add-on to standard of care or in a Sionna dual combination Sionna plans to advance SION-719 to a Phase 2a proof-of-concept add-on to standard of care trial in cystic fibrosis patients, and SION-451 to a Phase 1 healthy volunteer dual combination trial Next trials to initiate in the second half of 2025 with topline data expected in mid-2026 Sionna to hold a conference call today at 8:00 a.m. ET WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revo

    6/4/25 7:00:00 AM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care